Medpace (NASDAQ:MEDP) Stock Lifted to Hold by UBS Group

UBS Group upgraded shares of Medpace (NASDAQ:MEDP) to a hold rating in a report released on Wednesday morning,Zacks reports.

Several other research analysts have also commented on MEDP. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. BMO Capital Markets boosted their price target on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. TD Cowen increased their price target on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Royal Bank Of Canada raised their price objective on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Finally, Barclays set a $600.00 price objective on Medpace in a research report on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat, Medpace presently has a consensus rating of “Hold” and an average price target of $602.27.

Medpace Stock Up 0.3%

Shares of Medpace stock opened at $624.18 on Wednesday. The company has a market cap of $17.42 billion, a PE ratio of 36.59, a P/E/G ratio of 2.78 and a beta of 1.15. The business has a 50 day moving average of $600.14 and a 200 day moving average of $519.59. Medpace has a 52 week low of $373.00 and a 52 week high of $677.90.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm’s revenue was up 17.2% on a year-over-year basis. During the same quarter last year, the firm posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts anticipate that Medpace will post 17.54 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO August Troendle sold 49,018 shares of the business’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $628.11, for a total transaction of $30,788,695.98. Following the sale, the chief executive officer owned 433,372 shares in the company, valued at approximately $272,205,286.92. The trade was a 10.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders sold a total of 287,473 shares of company stock worth $177,687,399 over the last ninety days. Company insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in Medpace during the second quarter worth about $1,323,047,000. State Street Corp increased its stake in shares of Medpace by 4.2% during the second quarter. State Street Corp now owns 710,895 shares of the company’s stock valued at $376,483,000 after purchasing an additional 28,666 shares in the last quarter. Wasatch Advisors LP increased its stake in shares of Medpace by 19.4% during the first quarter. Wasatch Advisors LP now owns 773,931 shares of the company’s stock valued at $371,634,000 after purchasing an additional 125,625 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Medpace by 8.3% during the first quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock valued at $242,337,000 after purchasing an additional 38,760 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of Medpace by 19.4% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 375,033 shares of the company’s stock valued at $210,637,000 after purchasing an additional 60,883 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: UBS upgraded Medpace to “Neutral” from “Sell” and raised its price target to $673 from $405. The sharp target increase suggests UBS believes the company’s earnings outlook and recent share-price momentum have improved, even though the firm does not yet recommend buying the stock. UBS upgrades Medpace and raises price target
• Positive Sentiment: Medpace reported 17.2% second-quarter revenue growth. Its latest results also showed earnings per share of $4.25, above the $3.98 consensus estimate, while revenue of $707.33 million exceeded expectations of $689.51 million. Full-year 2026 earnings guidance remains $17.25-$17.95 per share, supporting the bullish fundamental case. Medpace reports second-quarter revenue growth
• Positive Sentiment: MEDP rose while the broader market declined. The relative strength indicates investors continued to favor the contract research organization after its earnings beat and revenue growth. Medpace rises as the market dips
• Neutral Sentiment: Analysts maintain an overall “Hold” consensus, with three Buy ratings and nine Holds and an average price target of $595.20. This target is below recent trading levels, suggesting valuation has already captured much of the expected improvement. Medpace receives average Hold rating
• Negative Sentiment: CEO August Troendle sold a combined 2,564 shares for roughly $1.59 million. The sales represent less than 1% of his holdings, so they are a modest negative signal rather than a major change in insider conviction. Medpace insider share sale

Medpace Company Profile

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.